Publikationen in Zusammenarbeit mit Forschern von Oslo University Hospital (7)

2024

  1. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee

    The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387

  2. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

    Blood, Vol. 143, Núm. 17, pp. 1713-1725

2022

  1. Corrigendum to “P-137: ITHACA, A Randomized Multicenter Phase 3 Study of Isatuximab in Combination With Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma: Safety Run-in Preliminary Results” [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) S109- S110] (Clinical Lymphoma, Myeloma and Leukemia (2021) 21(S2) (S1–S189), (S2152265021X00122))

    Clinical Lymphoma, Myeloma and Leukemia

  2. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

    New England Journal of Medicine, Vol. 386, Núm. 7, pp. 629-639

  3. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

    Nature Medicine, Vol. 28, Núm. 2, pp. 325-332

2016

  1. Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale

    Leukemia, Vol. 30, Núm. 9, pp. 1844-1852

2014

  1. Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database

    Nature Genetics, Vol. 46, Núm. 2, pp. 107-115